Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome

Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome

Cardiorenal syndrome encompasses a spectrum of disorders involving heart and kidney dysfunction, and sharing common risk factors, such as hypertension and diabetes. Clinical studies have shown that patients with and without diabetes may benefit from using sodium-glucose cotransporter 2 inhibitors to...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Konrad Urbanek, Donato Cappetta, Gabriella Bellocchio, Maria Antonietta Coppola, Paola Imbrici, Marialucia Telesca, Maria Donniacuo, Maria Antonietta Riemma, Elena Mele, Eleonora Cianflone, Silvio Naviglio, Elena Conte, Giulia Maria Camerino, Marco Mele, Mariarosaria Bucci, Giuseppe Castaldo, Annamaria De Luca, Francesco Rossi, Liberato Berrino, Antonella Liantonio, Antonella De Angelis
Médium: Artigo
Jazyk:angličtina
Vydáno: 2023
On-line přístup:https://doi.org/10.1016/j.phrs.2023.106659
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1016/j.phrs.2023.106659

Podobné jednotky